| Identification | Back Directory | [Name]
darglitazone | [CAS]
141200-24-0 | [Synonyms]
darglitazone
2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-
5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione | [Molecular Formula]
C23H20N2O4S | [MOL File]
141200-24-0.mol | [Molecular Weight]
420.48 |
| Chemical Properties | Back Directory | [density ]
1.306±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:20.0(Max Conc. mg/mL);47.56(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);47.56(Max Conc. mM) | [form ]
A crystalline solid | [pka]
6.22±0.50(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
Hypoglycemic (oral). | [in vivo]
Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24 h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult[1]. | Animal Model: | Male diabetic ob/ob mice[1] | | Dosage: | 1?mg/kg | | Administration: | Oral administration; daily; for 7 days | | Result: | Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice.
|
| [IC 50]
PPAR-γ |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|